Allergy News and Research

RSS

The term allergy encompasses a wide range of conditions; it is not a disease in itself. In 1906 Clemens von Pirquet was the first to describe allergies as a changed or altered reaction of the immune system in response to exposure to foreign proteins. These days the term allergy – medically termed hypersensitivity, signifies an exaggerated reaction to foreign substances.

FDA approves Gardasil for prevention of anal cancer

The U.S. Food and Drug Administration today approved the vaccine Gardasil for the prevention of anal cancer and associated precancerous lesions due to human papillomavirus (HPV) types 6, 11, 16, and 18 in people ages 9 through 26 years.

23 Dec 2010

Wellcome Trust awards additional £390,000 for investigation of Allergen Delivery Inhibitors

Scientists at St George's, University of London and the University of Manchester have received an additional Seeding Drug Discovery award of £390,000 from the Wellcome Trust to explore a new class of experimental drugs that block the trigger of allergic reactions before symptoms show.

21 Dec 2010

Phadia to market diagnostic products in India

Import, sales and distribution of Phadia's allergy, asthma and autoimmunity diagnostics products, including ImmunoCAP and EliA, have been commercially approved by the Indian authorities.

20 Dec 2010

Study finds second skin barrier structure may play a role in eczema development

Like a fence or barricade intended to stop unwanted intruders, the skin serves as a barrier protecting the body from the hundreds of allergens, irritants, pollutants and microbes people come in contact with every day.

20 Dec 2010

Goji berries' components are available in fruits and vegetables

A University of Granada professor specialist in Nutrition explained that the species Lycium Barbarum -currently imported from China- comes from the Mediterranean regions and grows in other mild regions of the world. Also, he stated that "Goji berries will not have any positive effect on people that do not follow a balanced diet".

17 Dec 2010

NIAID renews funding of PRIME to develop mathematical models to study influenza infection

Mount Sinai School of Medicine today announced that the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has renewed funding of the Program for Research on Immune Modeling and Experimentation. This program seeks to develop easy-to-use, predictive mathematical models to better understand patterns of infection among individuals affected by the H1N1 and 1918 influenza viruses and other related viruses.

17 Dec 2010

HIV patient cured!

German researchers working with stem cell therapy have claimed they have cured an American patient with HIV and leukemia. Experts are wary of accepting the development at its face value and caution that there is a need for further research. Dr David Scadden, a co-director of the Harvard University Stem Cell Institute added, “Cured is a strong word. But this is very encouraging… from all indications, there was no residual virus… It’s as good an outcome as one could hope for.”

16 Dec 2010

Profectus' GENEVAX IL-12 pDNA adjuvant improves vaccine-induced response rate in Phase I HIV study

Profectus Biosciences, Inc., a leader in the development of therapeutic and preventive vaccines against infectious diseases and cancers, announced today that its GENEVAX™ IL-12 pDNA adjuvant has significantly improved the vaccine-induced response rate in a Phase I clinical study of an experimental DNA vaccine for the prevention of HIV infection.

15 Dec 2010

Study examines the impact on asthmatics related to common environmental mould

Scientists investigating the allergic reactions that asthmatics suffer towards a common mould have discovered that many people with asthma actually had the mould growing in their own lungs.

15 Dec 2010

BRIC researchers discover new protein that improves immune system

Researchers at BRIC, the University of Copenhagen, have discovered for the first time a protein normally found in the body that can act to prevent chronic tissue inflammation.

15 Dec 2010

Amira's clinical-stage DP2 receptor antagonist program data to be presented at Pacifichem 2010

Amira Pharmaceuticals, Inc. announced today that it will present preclinical and clinical data from its DP2 receptor antagonist program on December 17, 2010, at Pacifichem 2010 in Honolulu, Hawaii. The data from Amira's clinical-stage DP2 program will be delivered by Brian Stearns, Ph.D., in a presentation titled "Discovery and optimization of a novel series of DP2 antagonists with efficacy in mouse models of COPD and asthma."

15 Dec 2010

ISTA commences bepotastine besilate nasal spray Phase 2 study in seasonal allergic rhinitis

ISTA Pharmaceuticals, Inc., today announced it has initiated a Phase 2 clinical study of bepotastine besilate nasal spray for the treatment of symptoms associated with seasonal allergic rhinitis, the inflammation of the nasal passages caused by allergies. The randomized, placebo-controlled, parallel-group environmental study will evaluate the safety and efficacy of bepotastine besilate, dosed twice daily, in patients presenting with allergic rhinitis caused by one of the most potent seasonal allergy triggers, Mountain Cedar pollen.

14 Dec 2010

DARPA awards Pulmatrix $5.7 million grant to advance iCALM therapies

Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, today announced that it has been awarded a grant for $5.7 million from the Defense Advanced Research Projects Agency (DARPA), a component of the Department of Defense (DOD), focused on identifying and advancing novel technologies to support defense of our nation's soldiers and civilian population.

14 Dec 2010

Pruritic nodules and aluminium allergy arise after vaccinations or treatments for allergies

Allergic contact dermatitis from aluminium has previously been considered very unusual. However, there are now reports of pruritic nodules and aluminium allergy arising after vaccinations or treatments for allergies.

14 Dec 2010

Clinical trail shows 2009 H1N1 influenza vaccine safe and effective in asthma patients

Results from a government-sponsored clinical trial of inactivated 2009 H1N1 influenza vaccine in people with asthma indicate that a single dose of vaccine was safe and induced a strong immune response predictive of protection.

14 Dec 2010

Mouse study shows flu virus infection may protect against asthma

In a paper that suggests a new strategy to prevent asthma, scientists at Children's Hospital Boston and their colleagues report that the influenza virus infection in young mice protected the mice as adults against the development of allergic asthma.

14 Dec 2010

Drug to reverse immunological decline in aging

UCSF researchers have identified an existing medication that restores key elements of the immune system that, when out of balance, lead to a steady decline in immunity and health as people age.

14 Dec 2010

Apartment living exposes kids to more second-hand smoke

A new study finds that kids who live in apartments have more tobacco contaminants in their blood than those who live in houses, even if smokers in the household refrain from smoking at home.

13 Dec 2010

Phadia signs agreement to acquire Chinese marketing company, WKL

Phadia today announced that it has entered into an agreement to acquire 100 per cent of the shares in the Chinese marketing company WKL from the parent company MeiRui. The acquisition is made through AllergonAB, a wholly owned subsidiary of Phadia, and is subject to approval by Chinese authorities.

13 Dec 2010

Official guidelines for diagnosis, treatment and management of food allergies released

A collaborative, government-led effort to guide and standardize diagnosis, treatment and management of food allergies has resulted in the release of an official set of recommendations for physicians.

10 Dec 2010

Allergy News and Research

Further Reading

FDA approves Gardasil for prevention of anal cancer

Wellcome Trust awards additional £390,000 for investigation of Allergen Delivery Inhibitors

Phadia to market diagnostic products in India

Study finds second skin barrier structure may play a role in eczema development

Goji berries' components are available in fruits and vegetables

NIAID renews funding of PRIME to develop mathematical models to study influenza infection

HIV patient cured!

Profectus' GENEVAX IL-12 pDNA adjuvant improves vaccine-induced response rate in Phase I HIV study

Study examines the impact on asthmatics related to common environmental mould

BRIC researchers discover new protein that improves immune system

Amira's clinical-stage DP2 receptor antagonist program data to be presented at Pacifichem 2010

ISTA commences bepotastine besilate nasal spray Phase 2 study in seasonal allergic rhinitis

DARPA awards Pulmatrix $5.7 million grant to advance iCALM therapies

Pruritic nodules and aluminium allergy arise after vaccinations or treatments for allergies

Clinical trail shows 2009 H1N1 influenza vaccine safe and effective in asthma patients

Mouse study shows flu virus infection may protect against asthma

Drug to reverse immunological decline in aging

Apartment living exposes kids to more second-hand smoke

Phadia signs agreement to acquire Chinese marketing company, WKL

Official guidelines for diagnosis, treatment and management of food allergies released

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News